LFVN News & Events

LifeVantage announced the addition of Mike Edwards as chief technology officer. Most recently, Edwards served as CTO at a direct selling company.

LifeVantage Corporation announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration. In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP and SST were thoroughly examined. All 14 peptides were influenced in the desired direction, with key results including: GRP: +1,087% increase; TFF3: +116% increase; VIP: +100% increase; OXM: +77% increase; CCK: +69% increase.

Sees FY26 revenue $225M-$240M. Sees FY26 adjusted EBITDA $23M-$26M. The company continues to anticipate revenue in the second half of the fiscal year will be higher than the first half due to the seasonality associated with its MindBody product line and the impact of the LoveBiome acquisition. The company expects a full year tax rate of approximately 24% to 26%. This guidance reflects the current trends in the business. The company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2026.